https://www.biopharm.org.tw
+886-2-2655-8135
services@biopharm.org.twMain Product
To date, the treatment of many neurodegenerative diseases, including Alzheimer’s disease (AD),is still an unmet medical need. To develop new therapeutic strategies, NRT has successfully synthesized and optimizeda new chemical entity, J4, with a novel MOA and a first-in-class approach to treat AD and AD-associated sleep disorder by targeting the dysregulated nucleoside homeostasis in the brain and subsequently ameliorates neuronal energy failure. This approach also holds promise for benefiting other neurological disorders, such as Tuberous sclerosis complex (TSC).
J4, an ENT1 inhibitor ▪ Orally active and BBB-permeable ▪ Decent bioavailability (F=65%) ▪ No drug-drug interaction ▪ Potent efficacy - Improve memory, reduce Aβ/pTau load and restore sleep pattern ▪ Excellent non-clinical safety ▪ CMC well characterized - Kilogram-scale manufacture - Good stability (long term and accelerated stability tests) ▪ Strong IP position - Major markets well protected (USA, EP, Japan, China, Australia, Korea, etc.)
Business Interests
▪ Out-licensing ▪ Co-development
Contact Info
Ching-Wen Wu
Project Manager
+886-2-27899034
as0210292@gate.sinica.edu.tw